

## Anakinra

Cat. No.:	HY-108841
CAS No.:	143090-92-0
Molecular Formula:	C <sub>759</sub> H <sub>1186</sub> N <sub>208</sub> O <sub>232</sub> S <sub>10</sub>
Molecular Weight:	17257.6
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Anakinra (Raleukin) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Anakinra is the first biological agent to block the pro-inflammatory effects <sup>[1][2]</sup> .
IC <sub>50</sub> & Target	IL-1R <sup>[1]</sup> .
In Vivo	Combined Etanercept (5 mg/kg, ip) and Anakinra (100 mg/kg, ip, daily for 7 days) substantially improves marginal mass human islet engraftment in immunodeficient mice <sup>[2]</sup> . Anakinra enhances tumor growth inhibition in mice receiving peptide vaccination and β-(1-3),(1-6)-D-glucan <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Cvetkovic RS, et al. Anakinra. *BioDrugs*. 2002;16(4):303-11; discussion 313-4.

[2]. McCall M, et al. Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. *Am J Transplant*. 2012 Feb;12(2):322-9.

[3]. Harnack U, et al. IL-1 receptor antagonist anakinra enhances tumour growth inhibition in mice receiving peptide vaccination and beta-(1-3),(1-6)-D-glucan. *Anticancer Res*. 2010 Oct;30(10):3959-65.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA